Hudson Bay Capital Management
DMAAR

Hudson Bay Capital Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Hudson Bay Capital Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.8K Sell
1,701,546
-98,454
-5% -$10.4K ﹤0.01% 1187
2025
Q4 		$284K Hold
1,800,000
– – ﹤0.01% 929
2025
Q3 		$391K Hold
1,800,000
– – ﹤0.01% 944
2025
Q2 		$225K Hold
1,800,000
– – ﹤0.01% 1189
2025
Q1 		$234K Buy
+1,800,000
New +$253K ﹤0.01% 1132

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Hudson Bay Capital Management's DMAAR Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 5.5% in Q1 2026, selling an estimated $10.4K and leaving 1,701,546 shares worth $93.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1187.

Hudson Bay Capital Management first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $391K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Hudson Bay Capital Management held 1,701,546 shares of Drugs Made In America Acquisition Corp Rights worth $93.8K as of Q1 2026.
  • Hudson Bay Capital Management sold 98,454 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $10.4K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1187 holding.
  • Hudson Bay Capital Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
  • Hudson Bay Capital Management's Drugs Made In America Acquisition Corp Rights position peaked at $391K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.